A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)

Phase 3 Terminated 748 enrolled AbbVie

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.

Timeline

Start: 2017-02-07
Primary completion: 2019-11-20
Completion: 2019-11-20

Publications

Tanaka K, Isse K, Fujihira T, Takenoyama M, Saunders L, Bheddah S, Nakanishi Y, Okamoto I. Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer. Lung Cancer. 2018 Jan;115:116-120. doi: 10.1016/j.lungcan.2017.11.018. Epub 2017 Nov 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rovalpituzumab tesirine	Other / unclassified	0.3 mg/kg	Intravenous
Background	Dexamethasone	Small molecule	8 mg	Oral

A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)

Summary

Timeline

Publications

Drugs

Indications